Q-omics provides the consensus-scored AZGP1P1 profile across patient tissues and cancer cell-line models. AZGP1P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, AZGP1P1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, AZGP1P1 RNA expression shows 8,306 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and KIRC as cancer lineages where AZGP1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AZGP1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AZGP1P1 survival associations across molecular data types. AZGP1P1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AZGP1P1 RNA expression–survival associations across cancer types. High AZGP1P1 expression shows unfavorable associations in THCA and UCS, but favorable associations in KIRP, KIRC, LIHC and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for AZGP1P1 RNA expression.
This table summarizes AZGP1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AZGP1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AZGP1P1 shows lower tumor expression in KIRC, KIRP, KICH and LIHC and higher tumor expression in COAD and BRCA. The KIRC box plot shows higher AZGP1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.971, t-test p < 0.001).
This table shows molecular features associated with AZGP1P1 in patient tissues and cancer cell lines. In patient samples, AZGP1P1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
